| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. T...
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical com...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...
Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price targ...
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains ...
Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price targ...